News

Epclusa in combination with ribavirin is indicated for the treatment of pediatric patients 6 years and older or weighing at least 37 pounds with severe cirrhosis. The FDA

The company is working with the US Food & Drug Administration (FDA) to commence a randomised, double-blind and placebo-controlled phase III clinical trial in collaboration with the Biomedical

The late-stage study assessed the safety and efficacy of abrocitinib in adult patients with the skin condition, who were also on background topical therapy. According to Pfizer, the

The findings were published in two online articles ahead of print in The New England Journal of Medicine. The primary endpoints were achieved in all three trials. Namely,

A1AT deficiency is a genetic disorder that can cause lung and liver disease. Children with the liver manifestations of the disease may present with yellowing of the skin

Compared to traditional vaccines, the DNA-based vaccine will directly induce a plasmid for encoding the antigen against which an immune response is required and depends on the production

Imfinzi gave the desired result for the company through its combination with a choice of standard-of-care (SoC) chemotherapies in the first line setting in patients with the lung

Upon execution of this Agreement, AJU will obtain the exclusive license to develop and sell the Product containing RBM-007 (the “Product”) in the Territory. RIBOMIC will receive an

In these studies, the primary efficacy endpoints were met for the gefapixant 45 mg twice daily treatment arms – demonstrating a statistically significant decrease in 24-hour coughs per